Cepheid (CPHD) 10-Q 6 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 22, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'CPHD	'
Entity Registrant Name	'CEPHEID	'
Entity Central Index Key	'0001037760	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	69,724,356

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$136,718	$66,072
Short-term investments	131,035	8,837
Accounts receivable, net	56,602	52,202
Inventory	119,564	103,866
Prepaid expenses and other current assets	19,493	13,037
Total current assets	463,412	244,014
Property and equipment, net	96,949	84,886
Investments	123,552	9,820
Other non-current assets	7,633	958
Intangible assets, net	14,326	15,245
Goodwill	39,681	39,681
Total assets	745,553	394,604
Current liabilities:	'	'
Accounts payable	60,924	52,609
Accrued compensation	20,413	22,009
Accrued royalties	3,884	5,245
Accrued and other liabilities	7,270	7,440
Current portion of deferred revenue	9,978	8,183
Total current liabilities	102,469	95,486
Long-term portion of deferred revenue	3,708	3,424
Convertible senior notes, net	271,207	'
Other liabilities	15,067	10,454
Total liabilities	392,451	109,364
Commitments and contingencies (Note 8)	'	'
Shareholders' equity:	'	'
Preferred stock, no par value; 5,000,000 shares authorized, none issued or outstanding	'	'
Common stock, no par value; 100,000,000 shares authorized, 69,697,715 and 68,556,392 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively	405,010	383,379
Additional paid-in capital	201,042	145,900
Accumulated other comprehensive loss	-84	-476
Accumulated deficit	-252,866	-243,563
Total shareholders' equity	353,102	285,240
Total liabilities and shareholders' equity	$745,553	$394,604

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]	'	'
Preferred stock, par value	$0	$0
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0	$0
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	69,697,715	68,556,392
Common stock, shares outstanding	69,697,715	68,556,392

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Income Statement [Abstract]	'	'
Sales	$106,907	$91,938
Costs and operating expenses:	'	'
Cost of sales	53,083	42,892
Collaboration profit sharing	1,291	2,110
Research and development	21,740	17,727
Sales and marketing	23,458	19,126
General and administrative	13,667	9,763
Total costs and operating expenses	113,239	91,618
Income (loss) from operations	-6,332	320
Other income (expense):	'	'
Interest and other income, net	153	1
Interest expense	-1,862	-35
Foreign currency exchange gain (loss) and other	-582	408
Other income (loss), net	-2,291	374
Income (loss) before income taxes	-8,623	694
Provision for income taxes	-680	-381
Net income (loss)	($9,303)	$313
Basic net income (loss) per share	($0.13)	$0
Diluted net income (loss) per share	($0.13)	$0
Shares used in computing basic net income (loss) per share	69,272	66,824
Shares used in computing diluted net income (loss) per share	69,272	69,406

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Income (Loss) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Statement Of Income And Comprehensive Income [Abstract]	'	'
Net income (loss)	($9,303)	$313
Change in unrealized gains and losses related to cash flow hedges:	'	'
Gain recognized in other comprehensive income	180	735
(Gain)/Loss reclassified from accumulated comprehensive income to the statement of operations	274	-34
Change in unrealized gains and losses related to available-for-sale investments, net:	'	'
Loss recognized in other comprehensive income	-60	'
(Gain) reclassified from accumulated comprehensive income to the statement of operations	-2	'
Comprehensive income (loss)	($8,911)	$1,014

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Statement Of Income And Comprehensive Income [Abstract]	'	'
Other comprehensive income (loss), tax	$0	$0

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Net income (loss)	($9,303)	$313
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:	'	'
Depreciation and amortization of property and equipment	4,977	3,768
Amortization of intangible assets	919	1,560
Unrealized exchange differences	-52	444
Amortization of debt discount and transaction costs	1,257	'
Stock-based compensation related to employees and consulting services rendered	6,782	6,277
Changes in operating assets and liabilities:	'	'
Accounts receivable	-4,400	-1,047
Inventory	-15,270	-7,814
Prepaid expenses and other current assets	-5,842	-3,528
Other non-current assets	122	168
Accounts payable and other current and non-current liabilities	3,470	8,342
Accrued compensation	-1,595	-614
Deferred revenue	2,079	2,608
Net cash provided by (used in) operating activities	-16,856	10,477
Cash flows from investing activities:	'	'
Capital expenditures	-8,762	-8,929
Payment for a technology license	'	-1,000
Proceeds from sales of marketable securities and investments	18,788	'
Proceeds from maturities of marketable securities and investments	4,650	'
Purchases of marketable securities and investments	-259,553	'
Net cash used in investing activities	-244,877	-9,929
Cash flows from financing activities:	'	'
Net proceeds from the issuance of common shares and exercise of stock options	21,631	6,145
Proceeds from borrowings of convertible senior notes, net of issuance costs	335,789	'
Purchase of convertible note capped call hedge	-25,082	'
Principal payment of notes payable	-48	-41
Net cash provided by financing activities	332,290	6,104
Effect of exchange rate change on cash	89	-443
Net increase in cash and cash equivalents	70,646	6,209
Cash and cash equivalents at beginning of period	66,072	95,779
Cash and cash equivalents at end of period	$136,718	$101,988

Organization_and_Summary_of_Si

Organization and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Organization and Summary of Significant Accounting Policies	'
	1. Organization and Summary of Significant Accounting Policies
	Organization and Basis of Presentation
	Cepheid (the “Company”) was incorporated in the State of California on March 4, 1996. The Company is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for testing in the Clinical market, as well as for application in the Company’s Non-Clinical legacy market. The Company’s systems enable rapid, sophisticated molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.
	The Condensed Consolidated Balance Sheet at March 31, 2014, the Condensed Consolidated Statements of Operations for the three months ended March 31, 2014 and 2013, the Condensed Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 31, 2014 and 2013 and the Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2014 and 2013 are unaudited. In the opinion of management, these condensed consolidated financial statements reflect all normal recurring adjustments that management considers necessary for a fair presentation of the Company’s financial position at such dates and the operating results and cash flows for those periods. The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S.”). However, certain information or footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The results of operations for such periods are not necessarily indicative of the results expected for the remainder of 2014 or for any future period. The Condensed Consolidated Balance Sheet as of December 31, 2013 is derived from audited financial statements as of that date but does not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Within the Condensed Consolidated Balance Sheet, certain amounts have been reclassified to conform to the current period presentation.
	Use of Estimates
	The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from these estimates.
	Cash, Cash Equivalents, Short-Term Investments and Investments
	Cash and cash equivalents consist of cash on deposit with banks and money market instruments. Interest and other income, net includes interest, dividends, amortization of purchase premiums and discounts and realized gains and losses on sales of securities.
	All highly liquid investments with maturities of three months or less at the date of purchase are classified as cash equivalents. The Company’s marketable debt securities have been classified and accounted for as available-for-sale. The Company determines the appropriate classification of its investments at the time of purchase and re-evaluates the designations at each balance sheet date. The Company classifies its marketable debt securities as cash equivalents, short-term investments or long-term investments based on each instrument’s underlying contractual and effective maturity date. All highly liquid investments with maturities of three months or less at the date of purchase are classified as cash equivalents. Marketable debt securities with effective maturities of 12 months or less are classified as short-term and marketable debt securities with effective maturities greater than 12 months are classified as long-term. The Company’s marketable debt securities are carried at fair value, with the unrealized gains and losses reported as a component of shareholders’ equity. The cost of securities sold is based upon the specific identification method.
	The Company assesses whether an other-than-temporary impairment loss on its investments has occurred due to declines in fair value or other market conditions. With respect to the Company’s debt securities, this assessment takes into account the severity and duration of the decline in value, the Company’s intent to sell the security, whether it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis, and whether or not the Company expects to recover the entire amortized cost basis of the security (that is, a credit loss exists).
	See Note 3, “Investments,” for information and related disclosures regarding the Company’s investments.
	Concentration of Credit Risks and Other Uncertainties
	The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Derivative instruments and investments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company’s derivative instruments consist of large financial institutions of high credit standing.
	The Company’s main financial institution for banking operations held 75% and 55% of the Company’s cash and cash equivalents as of March 31, 2014 and December 31, 2013, respectively.
	The Company’s accounts receivable are derived from net revenue to customers and distributors located in the United States and other countries. The Company performs credit evaluations of its customers’ financial condition. The Company provides reserves for potential credit losses but has not experienced significant losses to date. There was one direct customer whose accounts receivable balance represented 22% and 14% of total accounts receivable as of March 31, 2014 and December 31, 2013, respectively.
	The Company currently sells products through its direct sales force and distributors. There were no direct customers that accounted for 10% or more of total sales for the three months ended March 31, 2014 and 2013. No single country outside of the United States represented more than 10% of the Company’s total sales in any period presented.
	Inventory
	Inventory is stated at the lower of standard cost (which approximates actual cost) or market cost, with cost determined on the first-in-first-out method. Accordingly, allocation of fixed production overheads to conversion costs is based on normal capacity of production. Abnormal amounts of idle facility expense, freight, handling costs and spoilage are expensed as incurred and not included in overhead. In addition, unrecognized stock-based compensation cost of $2.6 million and $2.1 million was included in inventory as of March 31, 2014 and December 31, 2013, respectively.
	The following table summarizes the components of inventory (in thousands):
		March 31, 2014			December 31, 2013
	Raw Materials	$	40,140		$	35,760
	Work in Process		37,221			36,580
	Finished Goods		42,203			31,526
	Inventory	$	119,564		$	103,866
	Revenue Recognition
	The Company recognizes revenue from sales when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable and collectability is reasonably assured. No right of return exists for the Company’s products except in the case of damaged goods. The Company has not experienced any significant returns of its products. Shipping and handling costs are expensed as incurred and included in cost of sales. In those cases where the Company bills shipping and handling costs to customers, the amounts billed are classified as revenue.
	The Company enters into revenue arrangements that may consist of multiple deliverables of its products and services. In situations with multiple deliverables, revenue is recognized upon the delivery of the separate elements. The Company sells service contracts for which revenue is deferred and recognized ratably over the contract period.
	For multiple element arrangements, the total consideration for an arrangement is allocated among the separate elements in the arrangement based on a selling price hierarchy. The selling price hierarchy for a deliverable is based on: (1) vendor specific objective evidence (“VSOE”), if available; (2) third party evidence of selling price if VSOE is not available; or (3) an estimated selling price, if neither VSOE nor third party evidence is available. Estimated selling price is the Company’s best estimate of the selling price of an element in a transaction. The Company limits the amount of revenue recognized for delivered elements to the amount that is not contingent on the future delivery of products or services or other future performance obligations. The Company recognizes revenue for delivered elements only when the Company determines there are no uncertainties regarding customer acceptance.
	Revenue includes fees for technology licenses and research and development services, including research and development under grants and government sponsored research, royalties under license and collaboration agreements. Fees for technology licenses are generally fully recognized only after the license period has commenced, the technology has been delivered and no further involvement of the Company is required. When the Company has continuing involvement related to a technology license, revenue is recognized over the license term. Revenue related to research and development services is recognized as the related service is performed based on the performance requirements of the relevant contract. Under such agreements, the Company is required to perform specific research and development activities and is compensated either based on the costs or costs plus a mark-up associated with each specific contract over the term of the agreement or based on the Company’s progress to completion and recoverability is reasonably assured. Royalties are typically based on licensees’ net sales of products that utilize the Company’s technology and royalty revenues are recognized as earned in accordance with the contract terms when the royalties can be reliably measured and their collectability is reasonably assured, such as upon the receipt of a royalty statement from the customer. Advance payments received in excess of amounts earned, such as funds received in advance of products to be delivered or services to be performed, are classified as deferred revenue until earned.
	Net Income (Loss) per Share
	Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of common and common equivalent shares outstanding during the period. Stock options, employee stock purchases, restricted stock awards, restricted stock units and shares issuable upon a potential conversion of the convertible senior notes that could potentially dilute basic earnings per share in the future were not included in the computation of diluted earnings per share because to do so would have been antidilutive for the periods presented. These anti-dilutive common stock equivalent shares totaled 8,129,000 and 2,372,000 for the three months ended March 31, 2014 and 2013, respectively.
	The following summarizes the computation of basic and diluted income (loss) per share (in thousands, except for per share amounts):
		Three Months Ended March 31,
		2014			2013
	Basic:
	Net income (loss)	$	(9,303	)	$	313
	Basic weighted shares outstanding		69,272			66,824
	Net income (loss) per share	$	(0.13	)	$	0
	Diluted:
	Net income (loss)	$	(9,303	)	$	313
	Basic weighted shares outstanding		69,272			66,824
	Effect of dilutive securities:
	Stock options, ESPP, restricted stock units and restricted stock awards		—			2,582
	Diluted weighted shares outstanding		69,272			69,406
	Net income (loss) per share	$	(0.13	)	$	0

Fair_Value

Fair Value	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value	'
	2. Fair Value
	The following table summarizes the fair value hierarchy for the Company’s financial assets (cash, cash equivalents, short-term investments, foreign currency derivatives and long-term investments) and financial liabilities (foreign currency derivatives, convertible senior notes and contingent consideration) measured at fair value on a recurring basis as of March 31, 2014 and December 31, 2013 (in thousands):
	Balance as of March 31, 2014:
		Level 1		Level 2		Level 3		Total
	Assets:
	Cash and cash equivalents	$	72,127	$	64,591	$	—	$	136,718
	Short-term investments:
	Commercial paper		—		73,985		—		73,985
	Corporate debt securities		—		28,290		—		28,290
	Government agency securities		—		15,802		—		15,802
	Other securities		—		12,958		—		12,958
	Total short-term investments		—		131,035		—		131,035
	Foreign currency derivatives		—		1,140		—		1,140
	Investments:
	Corporate debt securities		—		42,542		—		42,542
	Government agency securities		—		26,091		—		26,091
	United States government securities		—		20,648		—		20,648
	Other securities		—		34,271		—		34,271
	Total investments		—		123,552		—		123,552
	Total	$	72,127	$	320,318	$	—	$	392,445
	Liabilities:
	Foreign currency derivatives	$	—	$	1,260	$	—	$	1,260
	Contingent consideration		—		—		258		258
	Total	$	—	$	1,260	$	258	$	1,518
	Balance as of December 31, 2013:
		Level 1		Level 2		Level 3		Total
	Assets:
	Cash and cash equivalents	$	64,772	$	1,300	$	—	$	66,072
	Short-term investments:
	Commercial paper		—		5,448		—		5,448
	Corporate debt securities		—		1,881		—		1,881
	Government agency securities		—		1,508		—		1,508
	Total short-term investments		—		8,837		—		8,837
	Foreign currency derivatives		—		873		—		873
	Investments:
	Corporate debt securities		—		1,975		—		1,975
	Government agency securities		—		3,405		—		3,405
	United States government securities		—		2,149		—		2,149
	Other securities		—		2,291		—		2,291
	Total investments		—		9,820		—		9,820
	Total	$	64,772	$	20,830	$	—	$	85,602
	Liabilities:
	Foreign currency derivatives	$	—	$	1,555	$	—	$	1,555
	Contingent consideration		—		—		310		310
	Total	$	—	$	1,555	$	310	$	1,865
	The Company’s financial instruments not measured at fair value on a recurring basis as of March 31, 2014 and December 31, 2013 were as follows (in thousands):
	Balance as of March 31, 2014:
		Level 1		Level 2		Level 3		Total
	Liabilities:
	Convertible senior notes	$	—	$	371,738	$	—	$	371,738
	Total	$	—	$	371,738	$	—	$	371,738
	Balance as of December 31, 2013:
		Level 1		Level 2		Level 3		Total
	Liabilities:
	Convertible senior notes	$	—	$	—	$	—	$	—
	Total	$	—	$	—	$	—	$	—
	The Company utilized levels 1 and 2 to value its financial assets on a recurring basis. Level 1 instruments use quoted prices in active markets for identical assets or liabilities, which include the Company’s cash accounts, short-term deposits and money market funds as these specific assets are liquid. Level 2 instruments are valued using the market approach which uses quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 instruments include commercial paper, corporate obligations, United States government securities, government agency securities and asset-backed securities as similar or identical instruments can be found in active markets.
	The Company recorded derivative assets and liabilities at fair value. The Company’s derivatives consist of foreign exchange forward contracts. The Company has elected to use the income approach to value the derivatives, using observable Level 2 market expectations at the measurement date and standard valuation techniques to convert future amounts to a single present amount assuming that participants are motivated, but not compelled to transact.
	Level 2 inputs for the valuations are limited to quoted prices for similar assets or liabilities in active markets (specifically foreign currency spot rate and forward points) and inputs other than quoted prices that are observable for the asset or liability (specifically LIBOR rates, credit default spot rates, and company specific LIBOR spread). Mid-market pricing is used as a practical expedient for fair value measurements. The fair value measurement of an asset or liability must reflect the nonperformance risk of the entity and the counterparty. Therefore, the impact of the counterparty’s creditworthiness when in an asset position and the Company’s creditworthiness when in a liability position has also been factored into the fair value measurement of the derivative instruments and did not have a material impact on the fair value of these derivative instruments. Both the counterparty and the Company are expected to continue to perform under the contractual terms of the instruments. The estimated fair value of the convertible senior notes, which we have classified as Level 2 financial instruments, was determined based on the quoted bid price of the convertible senior notes in an over-the-counter market on March 31, 2014.
	Level 3 liabilities, consisting of contingent consideration to be made in connection with the acquisition of a company in 2012 and an acquisition of certain assets in 2013, are valued by applying the income approach and are based on significant unobservable inputs that are supported by little or no market activity.

Investments

Investments	3 Months Ended
	Mar. 31, 2014
Investments Schedule [Abstract]	'
Investments	'
	3. Investments
	The Company’s marketable securities as of March 31, 2014 were classified as available-for-sale securities, with changes in fair value recognized in accumulated other comprehensive income (loss), a component of stockholders’ equity. Classification of marketable securities as a current asset is based on the intended holding period, effective maturity and realizability of the investment. The following tables summarize available-for-sale marketable securities (in thousands):
	Balance as of March 31, 2014:
		Cost			Gross Unrealized			Gross Unrealized			Estimated Fair
					Gain			Loss			Value
	Short-term investments:
	Commercial paper	$	138,551		$	25		$	—		$	138,576
	Corporate debt securities		28,308			2			(20	)		28,290
	Government agency securities		15,820			4			(22	)		15,802
	Other securities		12,955			3			—			12,958
	Amounts classified as cash equivalents		(64,583	)		(8	)		—			(64,591	)
	Total short-term investments	$	131,051		$	26		$	(42	)	$	131,035
	Investments:
	United States government securities	$	20,636		$	12		$	—		$	20,648
	Government agency securities		26,114			—			(23	)		26,091
	Corporate debt securities		42,578			5			(41	)		42,542
	Other securities		34,282			2			(13	)		34,271
	Total investments	$	123,610		$	19		$	(77	)	$	123,552
	Balance as of December 31, 2013:
		Cost			Gross Unrealized			Gross Unrealized			Estimated Fair
					Gain			Loss			Value
	Short-term investments:
	Commercial paper	$	6,747		$	1		$	—		$	6,748
	Corporate debt securities		1,881			—			—			1,881
	Government agency securities		1,506			2			—			1,508
	Amounts classified as cash equivalents		(1,300	)		—			—			(1,300	)
	Total short-term investments	$	8,834		$	3		$	—		$	8,837
	Investments:
	United States government securities	$	2,145		$	4		$	—		$	2,149
	Government agency securities		3,405			1			(1	)		3,405
	Corporate debt securities		1,970			5			—			1,975
	Other securities		2,290			1			—			2,291
	Total investments	$	9,810		$	11		$	(1	)	$	9,820
	For the three months ended March 31, 2014, $23.4 million of proceeds from sales and maturities of marketable securities were collected while no proceeds were received for the three months ended March 31, 2013. The Company determines gains and losses from sales of marketable securities based on specific identification of the securities sold. Gross realized gains and losses from sales of marketable securities, all of which are reported as a component of “Interest and other income, net” in the consolidated statements of operations, were for the three months ended March 31, 2014 and 2013 (in thousands):
		Three Months Ended March 31,
		2014			2013
	Gross realized gains	$	2		$	—
	Gross realized losses		—			—
	Realized gains, net	$	2		$	—
	The fair value of the Company’s marketable securities with unrealized losses at March 31, 2014 and December 31, 2013, and the duration of time that such losses had been unrealized (in thousands) were:
	Balance at March 31, 2014:
		Less Than 12 months						More than 12 months						Total
		Fair Value			Unrealized Loss			Fair Value			Unrealized Loss			Fair Value		Unrealized Loss
	Corporate debt securities	$	52,382		$	(61	)	$	—		$	—		$	52,382	$	(61	)
	Government agency securities		38,084			(45	)		—			—			38,084		(45	)
	Other securities		31,903			(13	)		—			—			31,903		(13	)
	Total	$	122,369		$	(119	)	$	—		$	—		$	122,369	$	(119	)
	Balance at December 31, 2013:
		Less Than 12 months						More than 12 months						Total
		Fair Value			Unrealized Loss			Fair Value			Unrealized Loss			Fair Value		Unrealized Loss
	Corporate debt securities	$	1,180		$	—		$	—		$	—		$	1,180	$	—
	Government agency securities		1,104			(1	)		—			—			1,104		(1	)
	Other securities		800			—			—			—			800		—
	Total	$	3,084		$	(1	)	$	—		$	—		$	3,084	$	(1	)
	The Company has evaluated such securities, which consist of investments in corporate debt, government agency and other securities as of March 31, 2014 and has determined that there was no indication of other-than-temporary impairments. This determination was based on several factors, including the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the debt issuer, and the Company’s intent and ability to hold the corporate securities for a period of time sufficient to allow for any anticipated recovery in market value.
	The following table summarizes the amortized cost and estimated fair value of available-for-sale debt securities at March 31, 2014 and December 31, 2013, by contractual maturity (in thousands):
		March 31, 2014						December 31, 2013
		Amortized Cost			Estimated Fair Value			Amortized Cost			Estimated Fair Value
	Debt securities:
	Mature in one year or less	$	168,366		$	168,374		$	10,134		$	10,137
	Mature after one year through three years		143,153			143,085			9,810			9,820
	Mature in more than three years		7,725			7,719			—			—
	Total	$	319,244		$	319,178		$	19,944		$	19,957

Derivative_Financial_Instrumen

Derivative Financial Instruments	3 Months Ended
	Mar. 31, 2014
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'
Derivative Financial Instruments	'
	4. Derivative Financial Instruments
	The Company uses derivatives to partially offset its business exposure to foreign currency exchange risk. The Company may enter into foreign currency forward contracts to offset some of the foreign exchange risk on expected future cash flows on certain forecasted revenue and cost of sales and on certain existing assets and liabilities.
	To help protect gross margins from fluctuations in foreign currency exchange rates, a portion of forecasted foreign currency revenue and expenses of certain of the Company’s subsidiaries are hedged. The Company typically hedges portions of its forecasted foreign currency exposure associated with revenue, cost of sales and operating expenses generally up to twelve months.
	The Company may also enter into foreign currency forward contracts to partially offset the foreign currency exchange gains and losses generated by the re-measurement of certain assets and liabilities. However, the Company may choose not to hedge certain foreign currency exchange exposures for a variety of reasons including, but not limited to, accounting considerations and the prohibitive economic cost of hedging particular exposures.
	The Company records all derivatives in the Condensed Consolidated Balance Sheet at fair value. The Company’s accounting treatment of these instruments is based on whether the instruments are designated as hedge or non-hedge instruments. The effective portions of cash flow hedges are recorded in accumulated other comprehensive income (loss) (“AOCI”) until the hedged item is recognized in earnings. The ineffective portions of cash flow hedges are recorded in foreign currency exchange gain (loss) and other. Gains and losses related to derivatives that are designated as hedging instruments are recorded in the financial statement line item to which the derivative relates.
	The Company had a net deferred loss associated with cash flow hedges of $0.2 million recorded in AOCI as of March 31, 2014. Deferred gains and losses associated with cash flow hedges of forecasted foreign currency revenue are recognized as a component of revenues in the same period as the related revenue is recognized, and deferred gains and losses related to cash flow hedges of forecasted expenses are recognized as a component of cost of sales, research and development expense, sales and marketing expense and general and administrative expense in the same period as the related expenses are recognized. The Company’s hedged transactions as of March 31, 2014 are expected to occur within twelve months.
	Derivative instruments designated as cash flow hedges must be de-designated as hedges when it is probable the forecasted hedged transaction will not occur in the initially identified time period or within a subsequent two-month time period. Deferred gains and losses in AOCI associated with such derivative instruments are reclassified immediately into foreign currency exchange gain (loss) and other. Any subsequent changes in fair value of such derivative instruments are reflected in foreign currency exchange gain (loss) and other unless they are re-designated as hedges of other transactions. The Company did not recognize any significant net gains or losses related to the loss of hedge designation on discontinued cash flow hedges during the three months ended March 31, 2014 and 2013.
	Gains or losses on derivatives not designated as hedging instruments are recorded in foreign currency exchange gain (loss) and other. During the three months ended March 31, 2014 and 2013, the Company recognized a loss of $0.3 million and a gain of $0.9 million, respectively, as a component of foreign currency exchange gain (loss) and other. These amounts represent the net gain or loss on the derivative contracts and do not include changes in the related exposures or ineffective portion or amounts excluded from the effectiveness testing of cash flow hedges.
	The notional principle amounts of the Company’s outstanding derivative instruments designated as cash flow hedges are $105.6 million and $96.6 million as of March 31, 2014 and December 31, 2013, respectively. The notional principle amounts of the Company’s outstanding derivative instruments not designated as cash flow hedges is $29.6 million and $24.2 million as of March 31, 2014 and December 31, 2013, respectively.
	The following tables show the Company’s derivative instruments at gross fair value as reflected in the Condensed Consolidated Balance Sheets as of March 31, 2014 and December 31, 2013, respectively (in thousands):
			March 31, 2014
			Fair Value of Derivates Designated			Fair Value of Derivates Not			Total Fair Value
			as Hedge Instruments			Designated as Hedge Instruments
	Derivative Assets (a):
	Foreign exchange contracts		$	867		$	273		$	1,140
	Derivative Liabilities (b):
	Foreign exchange contracts			(1,065	)		(195	)	$	(1,260	)
			31-Dec-13
			Fair Value of Derivates Designated			Fair Value of Derivates Not			Total Fair Value
			as Hedge Instruments			Designated as Hedge Instruments
	Derivative Assets (a):
	Foreign exchange contracts		$	782		$	91		$	873
	Derivative Liabilities (b):
	Foreign exchange contracts			(1,446	)		(109	)		(1,555	)
	(a)	The fair value of derivative assets is measured using Level 2 fair value inputs and is recorded as prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets.
	(b)	The fair value of derivative liabilities is measured using Level 2 fair value inputs and is recorded as accrued and other liabilities in the Condensed Consolidated Balance Sheets.
	The following tables show the pre-tax effect of the Company’s derivative instruments designated as cash flow hedges in the Condensed Consolidated Statements of Operations for the three month periods ended March 31, 2014 and 2013 (in thousands):
			Three Months Ended
			Gain Recognized in OCI -						Gain (Loss) Reclassified from					Gain (Loss) Recognized - Ineffective Portion and
			Effective Portion						AOCI into Income - Effective					Amount Excluded  from Effectiveness Testing
									Portion
			March 31,			March 31,			March 31,			March 31,		Location	March 31,		March 31,
			2014			2013			2014 (a)			2013 (b)			2014		2013
	Cash flow hedges:
	Foreign exchange contracts		$	180		$	735		$	(274	)	$	34	Foreign currency	$	—	$	(6	)
														exchange gain
														(loss) and
														other
	Total		$	180		$	735		$	(274	)	$	34		$	—	$	(6	)
	(a)	Includes gains and losses reclassified from AOCI into net income for the effective portion of cash flow hedges, of which a $0.5 million loss and a $0.2 million gain were recognized within sales and costs and operating expenses, respectively, within the Condensed Consolidated Statement of Operations for the three months ended March 31, 2014.
	(b)	Includes gains and losses reclassified from AOCI into net income for the effective portion of cash flow hedges, of which a $0.7 million loss and a $0.7 million gain were recognized within sales and costs and operating expenses, respectively, within the Condensed Consolidated Statement of Operations for the three months ended March 31, 2013.

Intangible_Assets_and_Goodwill

Intangible Assets and Goodwill	3 Months Ended
	Mar. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Intangible Assets and Goodwill	'
	5. Intangible Assets and Goodwill
	Intangible assets related to licenses are recorded at cost, less accumulated amortization. Intangible assets related to technology and other intangible assets acquired in acquisitions are recorded at fair value at the date of acquisition, less accumulated amortization. Intangible assets are amortized over their estimated useful lives, ranging from 3 to 15 years, on a straight-line basis. Amortization of intangible assets is primarily included in cost of sales, research and development and sales and marketing in the accompanying condensed consolidated statements of operations.
	The following table summarizes the recorded value and accumulated amortization of major classes of intangible assets (in thousands):
	Balance, March 31, 2014:	Gross Carrying		Accumulated			Net Carrying
		Amount		Amortization			Amount
	Licenses	$	28,577	$	(22,059	)	$	6,518
	Technology acquired in acquisitions		8,613		(8,613	)		—
	Customer relationships and other intangible assets acquired in acquisitions		15,748		(7,940	)		7,808
		$	52,938	$	(38,612	)	$	14,326
	Balance, December 31, 2013	Gross Carrying		Accumulated			Net Carrying
		Amount		Amortization			Amount
	Licenses	$	28,577	$	(21,597	)	$	6,980
	Technology acquired in acquisitions		8,613		(8,613	)		—
	Customer relationships and other intangible assets acquired in acquisitions		15,748		(7,483	)		8,265
		$	52,938	$	(37,693	)	$	15,245
	Amortization expense of intangible assets was $0.9 million and $1.6 million for the three months ended March 31, 2014 and 2013, respectively. The following table summarizes the expected future annual amortization expense of intangible assets recorded on the Company’s Condensed Consolidated Balance Sheet as of March 31, 2014, assuming no impairment charges (in thousands):
	For the Years Ending December 31,	Amortization
		Expense
	2014 (remaining nine months)	$	2,760
	2015		3,030
	2016		2,429
	2017		2,053
	2018		1,972
	Thereafter		2,082
	Total expected future annual amortization	$	14,326

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	6. Income Taxes
	For the three months ended March 31, 2014, the Company recorded an income tax provision of $0.7 million, primarily related to ordinary tax expense of the Company’s foreign subsidiaries. For the three months ended March 31, 2013, the Company recorded an income tax provision of $0.4 million, primarily related to ordinary tax expense of the Company’s foreign subsidiaries, partially offset by a tax benefit for research and development tax credits associated with our French subsidiary.
	The Company’s effective tax rate for the three months ended March 31, 2014 and March 31, 2013 differs from the statutory federal income tax rate of 34%, primarily due to the impact of operations in foreign jurisdictions, and losses in the U.S. federal and state jurisdictions for which no tax benefit is recorded. The difference in the effective tax rate for the three months ended March 31, 2014 and March 31, 2013 is primarily due to increased U.S. losses for the three months ended March 31, 2014 for which no income tax benefit is recorded in the US federal and state tax jurisdictions.
	The Company utilizes the liability method of accounting for income taxes. Under the liability method, deferred taxes are determined based on the temporary differences between the financial statement and tax bases of assets and liabilities using enacted tax rates. The Company’s position is to record a valuation allowance when it is more likely than not that some of the deferred tax assets will not be realized. Based on all available objective evidence, the Company believes that it is more likely than not that the net U.S. deferred tax assets will not be fully realized. Accordingly, the Company continues to maintain a full valuation allowance on its U.S. deferred tax assets and will do so until there is sufficient evidence to support the reversal of all or some portion of this valuation allowance.
	The Company or one of its subsidiaries files income tax returns in the United States federal jurisdiction and various state and foreign jurisdictions. The Company’s 2000 through 2013 tax years generally remain open to examination by U.S. federal and most state tax authorities. In addition, the Company files tax returns in multiple foreign taxing jurisdictions with open tax years ranging from 2008 to 2013.
	The Company anticipates that the total unrecognized tax benefits will not significantly change within the next 12 months due to the settlement of audits and the expiration of statutes of limitations. Currently, the Company has a tax audit in progress in Sweden. To the extent the final tax liabilities are different from the amounts originally accrued, the increases or decreases are recorded as income tax expense or benefit in the consolidated statements of operations. While the Company believes that the resolution of these audits will not have a material adverse effect on the Company’s results of operations, the outcome is subject to uncertainty.
	The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. For the periods presented, the amount of any interest or penalties related to uncertain tax positions was not material.

Convertible_Senior_Notes

Convertible Senior Notes	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Convertible Senior Notes	'
	7. Convertible Senior Notes
	In February 2014, the Company issued $345 million aggregate principal amount of 1.25% convertible senior notes (the “Notes”) due February 1, 2021, unless earlier repurchased by the Company or converted by the holder pursuant to their terms. Interest is payable semiannually in arrears on February 1 and August 1 of each year, commencing on August 1, 2014.
	The Notes are governed by an Indenture between the Company, as issuer, and Wells Fargo Bank, National Association, as trustee. The Notes are unsecured and rank: senior in right of payment to the Company’s future indebtedness that is expressly subordinated in right of payment to the Notes; equal in right of payment to the Company’s existing and future indebtedness that is not so subordinated; effectively subordinated in right of payment to any of the Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally subordinated to all existing and future indebtedness and other liabilities incurred by the Company’s subsidiaries.
	Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock or a combination of cash and shares of common stock, at the Company’s election.
	The Notes have an initial conversion rate of 15.3616 shares of common stock per $1,000 principal amount of Notes. This represents an initial effective conversion price of approximately $65.10 per share of common stock and approximately 5,300,000 shares upon conversion. Throughout the term of the Notes, the conversion rate may be adjusted upon the occurrence of certain events. Holders of the Notes will not receive any cash payment representing accrued and unpaid interest, if any, upon conversion of a Note, except in limited circumstances. Accrued but unpaid interest will be deemed to be paid by the cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock paid or delivered, as the case may be, to the holder upon conversion of a Note.
	Prior to the close of business on the business day immediately preceding August 1, 2020, the Notes will be convertible at the option of holders during certain periods, only upon satisfaction of certain conditions set forth below. On or after August 1, 2020, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their Notes at the conversion rate at any time regardless of whether the conditions set forth below have been met.
	Holders may convert all or a portion of their Notes prior to the close of business on the business day immediately preceding August 1, 2020, in multiples of $1,000 principal amount, only under the following circumstances:
		•		during any calendar quarter commencing after the calendar quarter ending on March 31, 2014 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;
		•		during the five business day period after any five consecutive trading day period (the “Notes Measurement Period”) in which the “trading price” (as the term is defined in the Indenture) per $1,000 principal amount of notes for each trading day of such Notes Measurement Period was less than 98% of the product of the last reported sale price of the Company’s common stock on such trading day and the conversion rate on each such trading day; or
		•		upon the occurrence of specified corporate events.
	As of March 31, 2014, the Notes are not yet convertible.
	Based on market data available for publicly traded, senior, unsecured corporate bonds issued by companies in the same industry and with similar maturity, the Company estimated the implied interest rate of its Notes to be approximately 5.0%, assuming no conversion option. Assumptions used in the estimate represent what market participants would use in pricing the liability component, including market interest rates, credit standing, and yield curves, all of which are defined as Level 2 observable inputs. The estimated implied interest rate was applied to the Notes, which resulted in a fair value of the liability component of $270 million upon issuance, calculated as the present value of implied future payments based on the $345 million aggregate principal amount. The excess of the principal amount of the liability component over its carrying amount (“debt discount”) is amortized to interest expense over the term of the Notes. The $75 million difference between the aggregate principal amount of $345 million and the estimated fair value of the liability component was recorded in additional paid-in capital as the Notes were not considered redeemable.
	In accounting for the transaction costs related to the issuance of the Notes, the Company allocated the total amount incurred to the liability and equity components based on their relative values. Issuance costs attributable to the liability component, totaling $7.2 million, are being amortized to expense over the term of the Notes, and issuance costs attributable to the equity component, totaling $2.0 million, and were netted with the equity component in stockholders’ equity.
	The Notes consist of the following (in thousands):
			March 31, 2014
	Liability component:
	Principal			345,000
	Less: debt discount, net of amortization			(73,793	)
	Net carrying amount			271,207
	Equity component (a)			73,013
		(a)	Recorded in the consolidated balance sheet within additional paid-in capital, net of $2.0 million issuance costs in equity
	The following table sets forth total interest expense recognized related to the Notes (in thousands):
			Three months ended
			March 31, 2014
	1.25% coupon		$	575
	Amortization of debt issuance costs			50
	Amortization of debt discount			1,207
				1,832
	As of March 31, 2014, the fair value of the Notes, which was determined based on inputs that are observable in the market or that could be derived from, or corroborated with, observable market data, quoted bid price of the Notes in an over-the-counter market (Level 2), and carrying value of debt instruments (carrying value excludes the equity component of the Company’s convertible notes classified in equity) were as follows (in thousands):
			March 31, 2014					December 31, 2013
			Fair Value			Carrying		Fair Value		Carrying
						Value				Value
	Convertible Senior Notes		$	371,738		$	271,207	$	—	$	—
	In connection with the issuance of the Notes, the Company entered into capped call transactions with certain counterparties affiliated with the initial purchasers and others. The capped call transactions are expected to reduce potential dilution of earnings per share upon conversion of the Notes. Under the capped call transactions, the Company purchased capped call options that in the aggregate relate to the total number of shares of the Company’s common stock underlying the Notes, with an initial strike price of approximately $65.10 per share, which corresponds to the initial conversion price of the Notes and is subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of the Notes, and have a cap price of approximately $78.61. The cost of the purchased capped calls of $25.1 million was recorded to stockholders’ equity and will not be re-measured.
	Based on the closing price of our common stock of $51.58 on March 31, 2014, the if-converted value of the Notes was less than their respective principal amounts.

Commitments_Contingencies_and_

Commitments, Contingencies and Legal Matters	3 Months Ended
	Mar. 31, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Commitments, Contingencies and Legal Matters	'
	8. Commitments, Contingencies and Legal Matters
	Purchase Commitments
	The following table summarizes the Company’s purchase commitments at March 31, 2014 (in thousands):
	Years Ending December 31,	Purchase Commitments
	2014 (remaining nine months)	$	27,626
	2015		1,944
	2016		1,716
	2017		1,716
	2018		—
	Thereafter		—
	Total minimum payments	$	33,002
	Purchase commitments include purchase orders or contracts for the purchase of raw materials used in the manufacturing of the Company’s systems and reagents.
	Legal Matters
	In May 2005, the Company entered into a license agreement with Roche that provided us with rights under a broad range of Roche patents, including patents relating to the PCR process, reverse transcription-based methods, nucleic acid quantification methods, real-time PCR detection process and composition, and patents relating to methods for detection of viral and cancer targets. A number of the licensed patents expired in the United States prior to the end of August of 2010 and in Europe prior to the end of August of 2011. In August 2010, the Company terminated the Company’s license to U.S. Patent No. 5,804,375 (the “375 Patent”) and ceased paying U.S.-related royalties. The Company terminated the entire license agreement in the fourth quarter of 2011. In August 2011, Roche initiated an arbitration proceeding against the Company in the International Chamber of Commerce pursuant to the terms of the terminated agreement. The Company filed an answer challenging arbitral jurisdiction over the issues submitted by Roche and denying that the Company violated any provision of the agreement. A three-member panel has been convened to address these issues in confidential proceedings. On July 30, 2013, the panel determined that it had jurisdiction to decide the claims, a determination that the Company appealed to the Swiss Federal Supreme Court. On October 2, 2013, the arbitration panel determined that it would proceed with the arbitration while this appeal was pending. On February 27, 2014 the Swiss Federal Supreme Court upheld the jurisdiction of the arbitration panel to hear the case, and the case is continuing. The Company believes that it has not violated any provision of the agreement and that the asserted claim of the 375 patent is expired, invalid, unenforceable, and not infringed.
	Management believes that it is reasonably possible that these legal proceedings could result in a material loss (i.e., the chance of the event occurring is more than remote but less than likely). However, given the nature of arbitration and the nature of the claims in this matter, the Company is unable to estimate the amount of such possible loss.
	On August 21, 2012 the Company filed a lawsuit against Roche Molecular Systems, Inc., and F. Hoffman-La Roche LTD, for a declaratory judgment of (a) invalidity, expiration, and non-infringement of 375 Patent; and (b) invalidity, unenforceability, expiration, and non-infringement of U.S. Patent No. 6,127,155 (the “155 Patent”). On January 17, 2013, the Court issued an order granting a motion by Roche to stay the suit with respect to the 375 Patent pending resolution of the above noted arbitration proceeding. In the same order, the Court dismissed the Company’s suit with respect to the 155 Patent for lack of subject matter jurisdiction, without considering or ruling on the merits of the Company’s case. The Court left open the possibility that the Company could re-file its case against the 155 Patent in the future. Management believes that the possibility that these legal proceedings will result in a material adverse effect on the Company’s business is remote.
	The Company may be subject to additional various claims, complaints and legal actions that arise from time to time in the normal course of business. Other than as described above, the Company does not believe it is party to any currently pending legal proceedings that will result in a material adverse effect on its business. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on the Company’s business, consolidated financial position, results of operations or cash flows.
	The Company responds to claims arising in the ordinary course of business. Should the Company not be able to secure the terms management expects, these estimates may change and will be recognized in the period in which they are identified. Although the ultimate outcome of such claims is not presently determinable, management believes that the resolution of these matters will not have a material adverse effect on the Company’s financial position, results of operations and cash flows.

Employee_Equity_Incentive_Plan

Employee Equity Incentive Plans and Stock-Based Compensation Expense	3 Months Ended
	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Employee Equity Incentive Plans and Stock-Based Compensation Expense	'
	9. Employee Equity Incentive Plans and Stock-Based Compensation Expense
	The following table summarizes stock-based compensation expense in the condensed consolidated statement of operations (in thousands):
		Three Months Ended
		March 31,
		2014			2013
	Cost of sales	$	381		$	541
	Research and development		2,128			1,805
	Sales and marketing		1,616			1,299
	General and administrative		2,657			2,632
	Total stock-based compensation expense	$	6,782		$	6,277
	The following table summarizes option activity under all plans (in thousands, except weighted average exercise price and weighted average remaining contractual term):
		Shares			Weighted			Weighted Average		Aggregate
					Average			Remaining		Instrinic Value
					Exercise Price			Contractual Term
	Outstanding, December 31, 2013		6,476		$	26.7
	Granted		149		$	49.65
	Exercised		(1,000	)	$	19.68
	Forfeited		(45	)	$	34.57
	Outstanding, March 31, 2014		5,580		$	28.5			3.96	$	128,916
	Exercisable, March 31, 2014		3,173		$	21.46			2.7	$	95,572
	Vested and expected to vest, March 31, 2014		5,370		$	28.09			3.89	$	126,279
	The following table summarizes restricted stock plan activity, which consists of restricted stock awards and restricted stock units (in thousands, except weighted average grant date fair value):
		Shares			Weighted
					Average
					Grant Date
					Fair Value
	Outstanding, December 31, 2013		742		$	34.13
	Granted		17			50.65
	Vested/Released		(58	)		31.88
	Cancelled		(20	)		37.26
	Outstanding, March 31, 2014		681		$	34.64
	The following table summarizes the assumptions used in determining the fair value of the Company’s stock options granted to employees and shares purchased by employees under the Company’s 2012 Employee Stock Purchase Plan (“ESPP”):
		Three Months Ended
		March 31,
		2014			2013
	OPTION SHARES:
	Expected Term (in years)		4.42			4.37
	Volatility		0.43			0.53
	Expected Dividends		—	%		—	%
	Risk Free Interest Rates		1.66	%		0.79	%
	Estimated Forfeitures		7.61	%		7.63	%
	Weighted Average Fair Value Per Share	$	18.43		$	15.57
	ESPP SHARES:
	Expected Term (in years)		1.25			1.25
	Volatility		0.32			0.46
	Expected Dividends		—	%		—	%
	Risk Free Interest Rates		0.17	%		0.19	%
	Weighted Average Fair Value Per Share	$	14.54		$	12.88

Segment_and_Significant_Concen

Segment and Significant Concentrations	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Segment and Significant Concentrations	'
	10. Segment and Significant Concentrations
	The Company and its wholly owned subsidiaries operate in one business segment.
	The following table summarizes total sales by type (in thousands):
		Three Months Ended
		March 31,
		2014		2013
	Sales:
	Systems and other sales	$	18,529	$	16,010
	Reagent and disposable sales		88,378		75,928
	Total sales	$	106,907	$	91,938
	The following table summarizes sales in the Clinical and Non-Clinical markets (in thousands):
		Three Months Ended
		March 31,
		2014		2013
	Sales by market:
	Clinical Systems	$	17,285	$	12,537
	Clinical Reagents		83,160		67,049
	Total Clinical		100,445		79,586
	Non-Clinical		6,462		12,352
	Total sales	$	106,907	$	91,938
	The Company currently sells products through its direct sales force and through third-party distributors. There were no customers that accounted for 10% or more of total sales for the three months ended March 31, 2014 and 2013. There was one direct customer whose accounts receivable balance represented 22% and 14% of total accounts receivable as of March 31, 2014 and December 31, 2013, respectively.
	The following table summarizes sales by geographic region (in thousands):
		Three Months Ended
		March 31,
		2014		2013
	Geographic sales information:
	North America
	Clinical	$	57,286	$	52,165
	Non-Clinical		5,549		11,391
	Total North America		62,835		63,556
	International
	Clinical	$	43,159	$	27,421
	Non-Clinical		913		961
	Total International		44,072		28,382
	Total sales	$	106,907	$	91,938
	No single country outside of the U.S. represented more than 10% of the Company’s total sales or total assets in any period presented. The Company recognized sales of $61.6 million and $59.6 million for sales to U.S. customers for the three months ended March 31, 2014 and 2013, respectively. As of March 31, 2014 and December 31, 2013, the Company has long lived-assets (excluding intangible assets) of $76.3 million and $63.9 million, respectively, which reside in the U.S. As of March 31, 2014 and December 31, 2013, the Company has long-lived assets of $20.6 million and $21.0 million, respectively, located outside of the U.S., which reside primarily in Sweden and countries in the European Monetary Union.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	11. Subsequent Events
	On April 22, 2014 the shareholders of the Company approved an amendment to the articles of incorporation of the Company to increase the number of authorized shares of our common stock from 100,000,000 to 150,000,000.

Organization_and_Summary_of_Si1

Organization and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Organization and Basis of Presentation	'
	Organization and Basis of Presentation
	Cepheid (the “Company”) was incorporated in the State of California on March 4, 1996. The Company is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for testing in the Clinical market, as well as for application in the Company’s Non-Clinical legacy market. The Company’s systems enable rapid, sophisticated molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.
	The Condensed Consolidated Balance Sheet at March 31, 2014, the Condensed Consolidated Statements of Operations for the three months ended March 31, 2014 and 2013, the Condensed Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 31, 2014 and 2013 and the Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2014 and 2013 are unaudited. In the opinion of management, these condensed consolidated financial statements reflect all normal recurring adjustments that management considers necessary for a fair presentation of the Company’s financial position at such dates and the operating results and cash flows for those periods. The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S.”). However, certain information or footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The results of operations for such periods are not necessarily indicative of the results expected for the remainder of 2014 or for any future period. The Condensed Consolidated Balance Sheet as of December 31, 2013 is derived from audited financial statements as of that date but does not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Within the Condensed Consolidated Balance Sheet, certain amounts have been reclassified to conform to the current period presentation.
Use of Estimates	'
	Use of Estimates
	The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from these estimates.
Cash, Cash Equivalents, Short-Term Investments and Investments	'
	Cash, Cash Equivalents, Short-Term Investments and Investments
	Cash and cash equivalents consist of cash on deposit with banks and money market instruments. Interest and other income, net includes interest, dividends, amortization of purchase premiums and discounts and realized gains and losses on sales of securities.
	All highly liquid investments with maturities of three months or less at the date of purchase are classified as cash equivalents. The Company’s marketable debt securities have been classified and accounted for as available-for-sale. The Company determines the appropriate classification of its investments at the time of purchase and re-evaluates the designations at each balance sheet date. The Company classifies its marketable debt securities as cash equivalents, short-term investments or long-term investments based on each instrument’s underlying contractual and effective maturity date. All highly liquid investments with maturities of three months or less at the date of purchase are classified as cash equivalents. Marketable debt securities with effective maturities of 12 months or less are classified as short-term and marketable debt securities with effective maturities greater than 12 months are classified as long-term. The Company’s marketable debt securities are carried at fair value, with the unrealized gains and losses reported as a component of shareholders’ equity. The cost of securities sold is based upon the specific identification method.
	The Company assesses whether an other-than-temporary impairment loss on its investments has occurred due to declines in fair value or other market conditions. With respect to the Company’s debt securities, this assessment takes into account the severity and duration of the decline in value, the Company’s intent to sell the security, whether it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis, and whether or not the Company expects to recover the entire amortized cost basis of the security (that is, a credit loss exists).
	See Note 3, “Investments,” for information and related disclosures regarding the Company’s investments.
Concentration of Credit Risks and Other Uncertainties	'
	Concentration of Credit Risks and Other Uncertainties
	The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Derivative instruments and investments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company’s derivative instruments consist of large financial institutions of high credit standing.
	The Company’s main financial institution for banking operations held 75% and 55% of the Company’s cash and cash equivalents as of March 31, 2014 and December 31, 2013, respectively.
	The Company’s accounts receivable are derived from net revenue to customers and distributors located in the United States and other countries. The Company performs credit evaluations of its customers’ financial condition. The Company provides reserves for potential credit losses but has not experienced significant losses to date. There was one direct customer whose accounts receivable balance represented 22% and 14% of total accounts receivable as of March 31, 2014 and December 31, 2013, respectively.
	The Company currently sells products through its direct sales force and distributors. There were no direct customers that accounted for 10% or more of total sales for the three months ended March 31, 2014 and 2013. No single country outside of the United States represented more than 10% of the Company’s total sales in any period presented.
Inventory	'
	Inventory
	Inventory is stated at the lower of standard cost (which approximates actual cost) or market cost, with cost determined on the first-in-first-out method. Accordingly, allocation of fixed production overheads to conversion costs is based on normal capacity of production. Abnormal amounts of idle facility expense, freight, handling costs and spoilage are expensed as incurred and not included in overhead. In addition, unrecognized stock-based compensation cost of $2.6 million and $2.1 million was included in inventory as of March 31, 2014 and December 31, 2013, respectively.
Revenue Recognition	'
	Revenue Recognition
	The Company recognizes revenue from sales when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable and collectability is reasonably assured. No right of return exists for the Company’s products except in the case of damaged goods. The Company has not experienced any significant returns of its products. Shipping and handling costs are expensed as incurred and included in cost of sales. In those cases where the Company bills shipping and handling costs to customers, the amounts billed are classified as revenue.
	The Company enters into revenue arrangements that may consist of multiple deliverables of its products and services. In situations with multiple deliverables, revenue is recognized upon the delivery of the separate elements. The Company sells service contracts for which revenue is deferred and recognized ratably over the contract period.
	For multiple element arrangements, the total consideration for an arrangement is allocated among the separate elements in the arrangement based on a selling price hierarchy. The selling price hierarchy for a deliverable is based on: (1) vendor specific objective evidence (“VSOE”), if available; (2) third party evidence of selling price if VSOE is not available; or (3) an estimated selling price, if neither VSOE nor third party evidence is available. Estimated selling price is the Company’s best estimate of the selling price of an element in a transaction. The Company limits the amount of revenue recognized for delivered elements to the amount that is not contingent on the future delivery of products or services or other future performance obligations. The Company recognizes revenue for delivered elements only when the Company determines there are no uncertainties regarding customer acceptance.
	Revenue includes fees for technology licenses and research and development services, including research and development under grants and government sponsored research, royalties under license and collaboration agreements. Fees for technology licenses are generally fully recognized only after the license period has commenced, the technology has been delivered and no further involvement of the Company is required. When the Company has continuing involvement related to a technology license, revenue is recognized over the license term. Revenue related to research and development services is recognized as the related service is performed based on the performance requirements of the relevant contract. Under such agreements, the Company is required to perform specific research and development activities and is compensated either based on the costs or costs plus a mark-up associated with each specific contract over the term of the agreement or based on the Company’s progress to completion and recoverability is reasonably assured. Royalties are typically based on licensees’ net sales of products that utilize the Company’s technology and royalty revenues are recognized as earned in accordance with the contract terms when the royalties can be reliably measured and their collectability is reasonably assured, such as upon the receipt of a royalty statement from the customer. Advance payments received in excess of amounts earned, such as funds received in advance of products to be delivered or services to be performed, are classified as deferred revenue until earned.
Net Income (Loss) per Share	'
	Net Income (Loss) per Share
	Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of common and common equivalent shares outstanding during the period. Stock options, employee stock purchases, restricted stock awards, restricted stock units and shares issuable upon a potential conversion of the convertible senior notes that could potentially dilute basic earnings per share in the future were not included in the computation of diluted earnings per share because to do so would have been antidilutive for the periods presented. These anti-dilutive common stock equivalent shares totaled 8,129,000 and 2,372,000 for the three months ended March 31, 2014 and 2013, respectively.
Derivative Financial Instruments	'
	The Company uses derivatives to partially offset its business exposure to foreign currency exchange risk. The Company may enter into foreign currency forward contracts to offset some of the foreign exchange risk on expected future cash flows on certain forecasted revenue and cost of sales and on certain existing assets and liabilities.
	To help protect gross margins from fluctuations in foreign currency exchange rates, a portion of forecasted foreign currency revenue and expenses of certain of the Company’s subsidiaries are hedged. The Company typically hedges portions of its forecasted foreign currency exposure associated with revenue, cost of sales and operating expenses generally up to twelve months.
	The Company may also enter into foreign currency forward contracts to partially offset the foreign currency exchange gains and losses generated by the re-measurement of certain assets and liabilities. However, the Company may choose not to hedge certain foreign currency exchange exposures for a variety of reasons including, but not limited to, accounting considerations and the prohibitive economic cost of hedging particular exposures.
	The Company records all derivatives in the Condensed Consolidated Balance Sheet at fair value. The Company’s accounting treatment of these instruments is based on whether the instruments are designated as hedge or non-hedge instruments. The effective portions of cash flow hedges are recorded in accumulated other comprehensive income (loss) (“AOCI”) until the hedged item is recognized in earnings. The ineffective portions of cash flow hedges are recorded in foreign currency exchange gain (loss) and other. Gains and losses related to derivatives that are designated as hedging instruments are recorded in the financial statement line item to which the derivative relates.
	The Company had a net deferred loss associated with cash flow hedges of $0.2 million recorded in AOCI as of March 31, 2014. Deferred gains and losses associated with cash flow hedges of forecasted foreign currency revenue are recognized as a component of revenues in the same period as the related revenue is recognized, and deferred gains and losses related to cash flow hedges of forecasted expenses are recognized as a component of cost of sales, research and development expense, sales and marketing expense and general and administrative expense in the same period as the related expenses are recognized. The Company’s hedged transactions as of March 31, 2014 are expected to occur within twelve months.
	Derivative instruments designated as cash flow hedges must be de-designated as hedges when it is probable the forecasted hedged transaction will not occur in the initially identified time period or within a subsequent two-month time period. Deferred gains and losses in AOCI associated with such derivative instruments are reclassified immediately into foreign currency exchange gain (loss) and other. Any subsequent changes in fair value of such derivative instruments are reflected in foreign currency exchange gain (loss) and other unless they are re-designated as hedges of other transactions.
Intangible Assets and Goodwill	'
	Intangible Assets and Goodwill
	Intangible assets related to licenses are recorded at cost, less accumulated amortization. Intangible assets related to technology and other intangible assets acquired in acquisitions are recorded at fair value at the date of acquisition, less accumulated amortization. Intangible assets are amortized over their estimated useful lives, ranging from 3 to 15 years, on a straight-line basis. Amortization of intangible assets is primarily included in cost of sales, research and development and sales and marketing in the accompanying condensed consolidated statements of operations.
Segment and Significant Concentrations	'
	Segment and Significant Concentrations
	The Company and its wholly owned subsidiaries operate in one business segment.

Organization_and_Summary_of_Si2

Organization and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Components of Inventories	'
	The following table summarizes the components of inventory (in thousands):
		March 31,			December 31,
		2014			2013
	Raw Materials	$	40,140		$	35,760
	Work in Process		37,221			36,580
	Finished Goods		42,203			31,526
	Inventory	$	119,564		$	103,866
Computation of Basic and Diluted Income (Loss) Per Share	'
	The following summarizes the computation of basic and diluted income (loss) per share (in thousands, except for per share amounts):
		Three Months Ended March 31,
		2014			2013
	Basic:
	Net income (loss)	$	(9,303	)	$	313
	Basic weighted shares outstanding		69,272			66,824
	Net income (loss) per share	$	(0.13	)	$	0
	Diluted:
	Net income (loss)	$	(9,303	)	$	313
	Basic weighted shares outstanding		69,272			66,824
	Effect of dilutive securities:
	Stock options, ESPP, restricted stock units and restricted stock awards		—			2,582
	Diluted weighted shares outstanding		69,272			69,406
	Net income (loss) per share	$	(0.13	)	$	0

Fair_Value_Tables

Fair Value (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Assets and Liabilities Measured at Fair Value on Recurring Basis	'
	The following table summarizes the fair value hierarchy for the Company’s financial assets (cash, cash equivalents, short-term investments, foreign currency derivatives and long-term investments) and financial liabilities (foreign currency derivatives, convertible senior notes and contingent consideration) measured at fair value on a recurring basis as of March 31, 2014 and December 31, 2013 (in thousands):
	Balance as of March 31, 2014:
		Level 1		Level 2		Level 3		Total
	Assets:
	Cash and cash equivalents	$	72,127	$	64,591	$	—	$	136,718
	Short-term investments:
	Commercial paper		—		73,985		—		73,985
	Corporate debt securities		—		28,290		—		28,290
	Government agency securities		—		15,802		—		15,802
	Other securities		—		12,958		—		12,958
	Total short-term investments		—		131,035		—		131,035
	Foreign currency derivatives		—		1,140		—		1,140
	Investments:
	Corporate debt securities		—		42,542		—		42,542
	Government agency securities		—		26,091		—		26,091
	United States government securities		—		20,648		—		20,648
	Other securities		—		34,271		—		34,271
	Total investments		—		123,552		—		123,552
	Total	$	72,127	$	320,318	$	—	$	392,445
	Liabilities:
	Foreign currency derivatives	$	—	$	1,260	$	—	$	1,260
	Contingent consideration		—		—		258		258
	Total	$	—	$	1,260	$	258	$	1,518
	Balance as of December 31, 2013:
		Level 1		Level 2		Level 3		Total
	Assets:
	Cash and cash equivalents	$	64,772	$	1,300	$	—	$	66,072
	Short-term investments:
	Commercial paper		—		5,448		—		5,448
	Corporate debt securities		—		1,881		—		1,881
	Government agency securities		—		1,508		—		1,508
	Total short-term investments		—		8,837		—		8,837
	Foreign currency derivatives		—		873		—		873
	Investments:
	Corporate debt securities		—		1,975		—		1,975
	Government agency securities		—		3,405		—		3,405
	United States government securities		—		2,149		—		2,149
	Other securities		—		2,291		—		2,291
	Total investments		—		9,820		—		9,820
	Total	$	64,772	$	20,830	$	—	$	85,602
	Liabilities:
	Foreign currency derivatives	$	—	$	1,555	$	—	$	1,555
	Contingent consideration		—		—		310		310
	Total	$	—	$	1,555	$	310	$	1,865
Liabilities Measured at Fair Value on Non-Recurring Basis	'
	The Company’s financial instruments not measured at fair value on a recurring basis as of March 31, 2014 and December 31, 2013 were as follows (in thousands):
	Balance as of March 31, 2014:
		Level 1		Level 2		Level 3		Total
	Liabilities:
	Convertible senior notes	$	—	$	371,738	$	—	$	371,738
	Total	$	—	$	371,738	$	—	$	371,738
	Balance as of December 31, 2013:
		Level 1		Level 2		Level 3		Total
	Liabilities:
	Convertible senior notes	$	—	$	—	$	—	$	—
	Total	$	—	$	—	$	—	$	—

Investments_Tables

Investments (Tables)	3 Months Ended
	Mar. 31, 2014
Investments Schedule [Abstract]	'
Schedule of Available-for-Sale Marketable Securities	'
	The following tables summarize available-for-sale marketable securities (in thousands):
	Balance as of March 31, 2014:
		Cost			Gross Unrealized			Gross Unrealized			Estimated Fair
					Gain			Loss			Value
	Short-term investments:
	Commercial paper	$	138,551		$	25		$	—		$	138,576
	Corporate debt securities		28,308			2			(20	)		28,290
	Government agency securities		15,820			4			(22	)		15,802
	Other securities		12,955			3			—			12,958
	Amounts classified as cash equivalents		(64,583	)		(8	)		—			(64,591	)
	Total short-term investments	$	131,051		$	26		$	(42	)	$	131,035
	Investments:
	United States government securities	$	20,636		$	12		$	—		$	20,648
	Government agency securities		26,114			—			(23	)		26,091
	Corporate debt securities		42,578			5			(41	)		42,542
	Other securities		34,282			2			(13	)		34,271
	Total investments	$	123,610		$	19		$	(77	)	$	123,552
	Balance as of December 31, 2013:
		Cost			Gross Unrealized			Gross Unrealized			Estimated Fair
					Gain			Loss			Value
	Short-term investments:
	Commercial paper	$	6,747		$	1		$	—		$	6,748
	Corporate debt securities		1,881			—			—			1,881
	Government agency securities		1,506			2			—			1,508
	Amounts classified as cash equivalents		(1,300	)		—			—			(1,300	)
	Total short-term investments	$	8,834		$	3		$	—		$	8,837
	Investments:
	United States government securities	$	2,145		$	4		$	—		$	2,149
	Government agency securities		3,405			1			(1	)		3,405
	Corporate debt securities		1,970			5			—			1,975
	Other securities		2,290			1			—			2,291
	Total investments	$	9,810		$	11		$	(1	)	$	9,820
Schedule of Gross Realized Gains and Losses of Marketable Securities	'
	Gross realized gains and losses from sales of marketable securities, all of which are reported as a component of “Interest and other income, net” in the consolidated statements of operations, were for the three months ended March 31, 2014 and 2013 (in thousands):
		Three Months Ended March 31,
		2014			2013
	Gross realized gains	$	2		$	—
	Gross realized losses		—			—
	Realized gains, net	$	2		$	—
Schedule of Marketable Securities with Unrealized Losses	'
	The fair value of the Company’s marketable securities with unrealized losses at March 31, 2014 and December 31, 2013, and the duration of time that such losses had been unrealized (in thousands) were:
	Balance at March 31, 2014:
		Less Than 12 months						More than 12 months						Total
		Fair Value			Unrealized Loss			Fair Value			Unrealized Loss			Fair Value		Unrealized Loss
	Corporate debt securities	$	52,382		$	(61	)	$	—		$	—		$	52,382	$	(61	)
	Government agency securities		38,084			(45	)		—			—			38,084		(45	)
	Other securities		31,903			(13	)		—			—			31,903		(13	)
	Total	$	122,369		$	(119	)	$	—		$	—		$	122,369	$	(119	)
	Balance at December 31, 2013:
		Less Than 12 months						More than 12 months						Total
		Fair Value			Unrealized Loss			Fair Value			Unrealized Loss			Fair Value		Unrealized Loss
	Corporate debt securities	$	1,180		$	—		$	—		$	—		$	1,180	$	—
	Government agency securities		1,104			(1	)		—			—			1,104		(1	)
	Other securities		800			—			—			—			800		—
	Total	$	3,084		$	(1	)	$	—		$	—		$	3,084	$	(1	)
Schedule of Amortized Cost and Estimated Fair Value of Available-for-Sale Debt Securities by Contractual Maturity	'
	The following table summarizes the amortized cost and estimated fair value of available-for-sale debt securities at March 31, 2014 and December 31, 2013, by contractual maturity (in thousands):
		March 31, 2014						December 31, 2013
		Amortized Cost			Estimated Fair Value			Amortized Cost			Estimated Fair Value
	Debt securities:
	Mature in one year or less	$	168,366		$	168,374		$	10,134		$	10,137
	Mature after one year through three years		143,153			143,085			9,810			9,820
	Mature in more than three years		7,725			7,719			—			—
	Total	$	319,244		$	319,178		$	19,944		$	19,957

Derivative_Financial_Instrumen1

Derivative Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2014
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'
Derivative Instruments at Gross Fair Value Reflected in Condensed Consolidated Balance Sheets	'
	The following tables show the Company’s derivative instruments at gross fair value as reflected in the Condensed Consolidated Balance Sheets as of March 31, 2014 and December 31, 2013, respectively (in thousands):
			March 31, 2014
			Fair Value of Derivates Designated			Fair Value of Derivates Not			Total Fair Value
			as Hedge Instruments			Designated as Hedge Instruments
	Derivative Assets (a):
	Foreign exchange contracts		$	867		$	273		$	1,140
	Derivative Liabilities (b):
	Foreign exchange contracts			(1,065	)		(195	)	$	(1,260	)
			31-Dec-13
			Fair Value of Derivates Designated			Fair Value of Derivates Not			Total Fair Value
			as Hedge Instruments			Designated as Hedge Instruments
	Derivative Assets (a):
	Foreign exchange contracts		$	782		$	91		$	873
	Derivative Liabilities (b):
	Foreign exchange contracts			(1,446	)		(109	)		(1,555	)
	(a)	The fair value of derivative assets is measured using Level 2 fair value inputs and is recorded as prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets.
	(b)	The fair value of derivative liabilities is measured using Level 2 fair value inputs and is recorded as accrued and other liabilities in the Condensed Consolidated Balance Sheets.
Pre-tax Effect of Derivative Instruments Designated as Cash Flow Hedges in Condensed Consolidated Statements of Operations	'
	The following tables show the pre-tax effect of the Company’s derivative instruments designated as cash flow hedges in the Condensed Consolidated Statements of Operations for the three month periods ended March 31, 2014 and 2013 (in thousands):
			Three Months Ended
			Gain Recognized in OCI -						Gain (Loss) Reclassified from					Gain (Loss) Recognized - Ineffective Portion and
			Effective Portion						AOCI into Income - Effective					Amount Excluded  from Effectiveness Testing
									Portion
			March 31,			March 31,			March 31,			March 31,		Location	March 31,		March 31,
			2014			2013			2014 (a)			2013 (b)			2014		2013
	Cash flow hedges:
	Foreign exchange contracts		$	180		$	735		$	(274	)	$	34	Foreign currency	$	—	$	(6	)
														exchange gain
														(loss) and
														other
	Total		$	180		$	735		$	(274	)	$	34		$	—	$	(6	)
	(a)	Includes gains and losses reclassified from AOCI into net income for the effective portion of cash flow hedges, of which a $0.5 million loss and a $0.2 million gain were recognized within sales and costs and operating expenses, respectively, within the Condensed Consolidated Statement of Operations for the three months ended March 31, 2014.
	(b)	Includes gains and losses reclassified from AOCI into net income for the effective portion of cash flow hedges, of which a $0.7 million loss and a $0.7 million gain were recognized within sales and costs and operating expenses, respectively, within the Condensed Consolidated Statement of Operations for the three months ended March 31, 2013.

Intangible_Assets_and_Goodwill1

Intangible Assets and Goodwill (Tables)	3 Months Ended
	Mar. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Net Carrying Value and Accumulated Amortization of Major Classes of Intangible Assets	'
	The following table summarizes the recorded value and accumulated amortization of major classes of intangible assets (in thousands):
	Balance, March 31, 2014:	Gross Carrying		Accumulated			Net Carrying
		Amount		Amortization			Amount
	Licenses	$	28,577	$	(22,059	)	$	6,518
	Technology acquired in acquisitions		8,613		(8,613	)		—
	Customer relationships and other intangible assets acquired in acquisitions		15,748		(7,940	)		7,808
		$	52,938	$	(38,612	)	$	14,326
	Balance, December 31, 2013	Gross Carrying		Accumulated			Net Carrying
		Amount		Amortization			Amount
	Licenses	$	28,577	$	(21,597	)	$	6,980
	Technology acquired in acquisitions		8,613		(8,613	)		—
	Customer relationships and other intangible assets acquired in acquisitions		15,748		(7,483	)		8,265
		$	52,938	$	(37,693	)	$	15,245
Expected Future Annual Amortization Expense of Intangible Assets	'
	The following table summarizes the expected future annual amortization expense of intangible assets recorded on the Company’s Condensed Consolidated Balance Sheet as of March 31, 2014, assuming no impairment charges (in thousands):
	For the Years Ending December 31,	Amortization
		Expense
	2014 (remaining nine months)	$	2,760
	2015		3,030
	2016		2,429
	2017		2,053
	2018		1,972
	Thereafter		2,082
	Total expected future annual amortization	$	14,326

Convertible_Senior_Notes_Table

Convertible Senior Notes (Tables)	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Schedule of Convertible Notes	'
	The Notes consist of the following (in thousands):
			March 31,
			2014
	Liability component:
	Principal			345,000
	Less: debt discount, net of amortization			(73,793	)
	Net carrying amount			271,207
	Equity component (a)			73,013
	(a)	Recorded in the consolidated balance sheet within additional paid-in capital, net of $2.0 million issuance costs in equity
Schedule of Total Interest Expense Related to Notes	'
	The following table sets forth total interest expense recognized related to the Notes (in thousands):
			Three months ended
			March 31, 2014
	1.25% coupon		$	575
	Amortization of debt issuance costs			50
	Amortization of debt discount			1,207
				1,832
Schedule of Carrying Value of Debt Instrument	'
	As of March 31, 2014, the fair value of the Notes, which was determined based on inputs that are observable in the market or that could be derived from, or corroborated with, observable market data, quoted bid price of the Notes in an over-the-counter market (Level 2), and carrying value of debt instruments (carrying value excludes the equity component of the Company’s convertible notes classified in equity) were as follows (in thousands):
			March 31, 2014					December 31, 2013
			Fair Value			Carrying		Fair Value		Carrying
						Value				Value
	Convertible Senior Notes		$	371,738		$	271,207	$	—	$	—

Commitments_Contingencies_and_1

Commitments, Contingencies and Legal Matters (Tables)	3 Months Ended
	Mar. 31, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Summary of Purchase Commitments	'
	The following table summarizes the Company’s purchase commitments at March 31, 2014 (in thousands):
	Years Ending December 31,	Purchase Commitments
	2014 (remaining nine months)	$	27,626
	2015		1,944
	2016		1,716
	2017		1,716
	2018		—
	Thereafter		—
	Total minimum payments	$	33,002

Employee_Equity_Incentive_Plan1

Employee Equity Incentive Plans and Stock-Based Compensation Expense (Tables)	3 Months Ended
	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Summary of Stock-Based Compensation Expense	'
	The following table summarizes stock-based compensation expense in the condensed consolidated statement of operations (in thousands):
		Three Months Ended
		March 31,
		2014			2013
	Cost of sales	$	381		$	541
	Research and development		2,128			1,805
	Sales and marketing		1,616			1,299
	General and administrative		2,657			2,632
	Total stock-based compensation expense	$	6,782		$	6,277
Summary of Option Activity	'
	The following table summarizes option activity under all plans (in thousands, except weighted average exercise price and weighted average remaining contractual term):
		Shares			Weighted			Weighted Average		Aggregate
					Average			Remaining		Instrinic Value
					Exercise Price			Contractual Term
	Outstanding, December 31, 2013		6,476		$	26.7
	Granted		149		$	49.65
	Exercised		(1,000	)	$	19.68
	Forfeited		(45	)	$	34.57
	Outstanding, March 31, 2014		5,580		$	28.5			3.96	$	128,916
	Exercisable, March 31, 2014		3,173		$	21.46			2.7	$	95,572
	Vested and expected to vest, March 31, 2014		5,370		$	28.09			3.89	$	126,279
Summary of Restricted Stock Plan Activity	'
	The following table summarizes restricted stock plan activity, which consists of restricted stock awards and restricted stock units (in thousands, except weighted average grant date fair value):
		Shares			Weighted
					Average
					Grant
					Date Fair
					Value
	Outstanding, December 31, 2013		742		$	34.13
	Granted		17			50.65
	Vested/Released		(58	)		31.88
	Cancelled		(20	)		37.26
	Outstanding, March 31, 2014		681		$	34.64
Summary of Assumptions to Estimate Fair Value	'
	The following table summarizes the assumptions used in determining the fair value of the Company’s stock options granted to employees and shares purchased by employees under the Company’s 2012 Employee Stock Purchase Plan (“ESPP”):
		Three Months Ended
		March 31,
		2014			2013
	OPTION SHARES:
	Expected Term (in years)		4.42			4.37
	Volatility		0.43			0.53
	Expected Dividends		—	%		—	%
	Risk Free Interest Rates		1.66	%		0.79	%
	Estimated Forfeitures		7.61	%		7.63	%
	Weighted Average Fair Value Per Share	$	18.43		$	15.57
	ESPP SHARES:
	Expected Term (in years)		1.25			1.25
	Volatility		0.32			0.46
	Expected Dividends		—	%		—	%
	Risk Free Interest Rates		0.17	%		0.19	%
	Weighted Average Fair Value Per Share	$	14.54		$	12.88

Segment_and_Significant_Concen1

Segment and Significant Concentrations (Tables)	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Summary of Total Sales	'
	The following table summarizes total sales by type (in thousands):
		Three Months Ended
		March 31,
		2014		2013
	Sales:
	Systems and other sales	$	18,529	$	16,010
	Reagent and disposable sales		88,378		75,928
	Total sales	$	106,907	$	91,938
Sales Information by Segments	'
	The following table summarizes sales in the Clinical and Non-Clinical markets (in thousands):
		Three Months Ended
		March 31,
		2014		2013
	Sales by market:
	Clinical Systems	$	17,285	$	12,537
	Clinical Reagents		83,160		67,049
	Total Clinical		100,445		79,586
	Non-Clinical		6,462		12,352
	Total sales	$	106,907	$	91,938
Segment Sales by Geography Region	'
	The following table summarizes sales by geographic region (in thousands):
		Three Months Ended
		March 31,
		2014		2013
	Geographic sales information:
	North America
	Clinical	$	57,286	$	52,165
	Non-Clinical		5,549		11,391
	Total North America		62,835		63,556
	International
	Clinical	$	43,159	$	27,421
	Non-Clinical		913		961
	Total International		44,072		28,382
	Total sales	$	106,907	$	91,938

Organization_and_Summary_of_Si3

Organization and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Accounting Policies [Abstract]	'	'	'
Short-term marketable debt securities	'Maturities of 12 months or less	'	'
Long-term marketable debt securities	'Maturities greater than 12 months	'	'
Percentage of cash and cash equivalents held by the Company's	75.00%	'	55.00%
Maximum percentage of accounts receivable by any one customer	22.00%	'	14.00%
Percentage of direct customer to total sales	10.00%	10.00%	'
Maximum sales contribution by any other country outside of the United States, percentage	10.00%	'	'
Unrecognized stock-based compensation cost included in inventory	$2.60	'	$2.10
Total anti-dilutive common stock equivalent shares	8,129,000	2,372,000	'

Organization_and_Summary_of_Si4

Organization and Summary of Significant Accounting Policies - Components of Inventories (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw Materials	$40,140	$35,760
Work in Process	37,221	36,580
Finished Goods	42,203	31,526
Inventory	$119,564	$103,866

Organization_and_Summary_of_Si5

Organization and Summary of Significant Accounting Policies - Computation of Basic and Diluted Income (Loss) Per Share (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Basic:	'	'
Net income (loss)	($9,303)	$313
Basic weighted shares outstanding	69,272	66,824
Net income (loss) per share	($0.13)	$0
Diluted:	'	'
Net income (loss)	($9,303)	$313
Basic weighted shares outstanding	69,272	66,824
Effect of dilutive securities:	'	'
Stock options, ESPP, restricted stock units and restricted stock awards	'	2,582
Diluted weighted shares outstanding	69,272	69,406
Net income (loss) per share	($0.13)	$0

Fair_Value_Assets_and_Liabilit

Fair Value - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total short-term investments	$131,035	$8,837
Foreign currency derivatives	1,140	873
Total investments	123,552	9,820
Assets, Total	392,445	85,602
Foreign currency derivatives	1,260	1,555
Contingent consideration	258	310
Liabilities, Total	1,518	1,865
Amounts classified as cash equivalents [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash and cash equivalents	136,718	66,072
Commercial paper [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total short-term investments	73,985	5,448
Corporate debt securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total short-term investments	28,290	1,881
Total investments	42,542	1,975
Government agency securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total short-term investments	15,802	1,508
Total investments	26,091	3,405
United States government securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total investments	20,648	2,149
Other securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total short-term investments	12,958	'
Other securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total investments	34,271	2,291
Fair Value, Measurements, Recurring [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total short-term investments	'	'
Foreign currency derivatives	'	'
Total investments	'	'
Assets, Total	72,127	64,772
Foreign currency derivatives	'	'
Contingent consideration	'	'
Liabilities, Total	'	'
Fair Value, Measurements, Recurring [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total short-term investments	131,035	8,837
Foreign currency derivatives	1,140	873
Total investments	123,552	9,820
Assets, Total	320,318	20,830
Foreign currency derivatives	1,260	1,555
Contingent consideration	'	'
Liabilities, Total	1,260	1,555
Fair Value, Measurements, Recurring [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total short-term investments	'	'
Foreign currency derivatives	'	'
Total investments	'	'
Assets, Total	'	'
Foreign currency derivatives	'	'
Contingent consideration	258	310
Liabilities, Total	258	310
Fair Value, Measurements, Recurring [Member] | Amounts classified as cash equivalents [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash and cash equivalents	72,127	64,772
Fair Value, Measurements, Recurring [Member] | Amounts classified as cash equivalents [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash and cash equivalents	64,591	1,300
Fair Value, Measurements, Recurring [Member] | Amounts classified as cash equivalents [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash and cash equivalents	'	'
Fair Value, Measurements, Recurring [Member] | Commercial paper [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total short-term investments	'	'
Fair Value, Measurements, Recurring [Member] | Commercial paper [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total short-term investments	73,985	5,448
Fair Value, Measurements, Recurring [Member] | Commercial paper [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total short-term investments	'	'
Fair Value, Measurements, Recurring [Member] | Corporate debt securities [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total short-term investments	'	'
Total investments	'	'
Fair Value, Measurements, Recurring [Member] | Corporate debt securities [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total short-term investments	28,290	1,881
Total investments	42,542	1,975
Fair Value, Measurements, Recurring [Member] | Corporate debt securities [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total short-term investments	'	'
Total investments	'	'
Fair Value, Measurements, Recurring [Member] | Government agency securities [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total short-term investments	'	'
Total investments	'	'
Fair Value, Measurements, Recurring [Member] | Government agency securities [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total short-term investments	15,802	1,508
Total investments	26,091	3,405
Fair Value, Measurements, Recurring [Member] | Government agency securities [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total short-term investments	'	'
Total investments	'	'
Fair Value, Measurements, Recurring [Member] | United States government securities [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total investments	'	'
Fair Value, Measurements, Recurring [Member] | United States government securities [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total investments	20,648	2,149
Fair Value, Measurements, Recurring [Member] | United States government securities [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total investments	'	'
Fair Value, Measurements, Recurring [Member] | Other securities [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total short-term investments	'	'
Fair Value, Measurements, Recurring [Member] | Other securities [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total short-term investments	12,958	'
Fair Value, Measurements, Recurring [Member] | Other securities [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total short-term investments	'	'
Fair Value, Measurements, Recurring [Member] | Other securities [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total investments	'	'
Fair Value, Measurements, Recurring [Member] | Other securities [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total investments	34,271	2,291
Fair Value, Measurements, Recurring [Member] | Other securities [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total investments	'	'

Fair_Value_Liabilities_Measure

Fair Value - Liabilities Measured at Fair Value on Non-Recurring Basis (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Liabilities:	'	'
Liabilities, Total	$371,738	'
Level 2 [Member]	'	'
Liabilities:	'	'
Liabilities, Total	371,738	'
Convertible senior notes [Member]	'	'
Liabilities:	'	'
Liabilities, Total	371,738	'
Fair Value, Measurements, Nonrecurring [Member] | Level 1 [Member]	'	'
Liabilities:	'	'
Liabilities, Total	'	'
Fair Value, Measurements, Nonrecurring [Member] | Level 2 [Member]	'	'
Liabilities:	'	'
Liabilities, Total	371,738	'
Fair Value, Measurements, Nonrecurring [Member] | Level 3 [Member]	'	'
Liabilities:	'	'
Liabilities, Total	'	'
Fair Value, Measurements, Nonrecurring [Member] | Convertible senior notes [Member] | Level 1 [Member]	'	'
Liabilities:	'	'
Liabilities, Total	'	'
Fair Value, Measurements, Nonrecurring [Member] | Convertible senior notes [Member] | Level 2 [Member]	'	'
Liabilities:	'	'
Liabilities, Total	371,738	'
Fair Value, Measurements, Nonrecurring [Member] | Convertible senior notes [Member] | Level 3 [Member]	'	'
Liabilities:	'	'
Liabilities, Total	'	'

Investments_Schedule_of_Availa

Investments - Schedule of Available-for-Sale Marketable Securities (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Short-term investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale marketable securities, Cost	$131,051	$8,834
Available-for-sale marketable securities, Gross Unrealized Gain	26	3
Available-for-sale marketable securities, Gross Unrealized Loss	-42	'
Available-for-sale marketable securities, Estimated Fair Value	131,035	8,837
Short-term investments [Member] | Commercial paper [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale marketable securities, Cost	138,551	6,747
Available-for-sale marketable securities, Gross Unrealized Gain	25	1
Available-for-sale marketable securities, Gross Unrealized Loss	'	'
Available-for-sale marketable securities, Estimated Fair Value	138,576	6,748
Short-term investments [Member] | Corporate debt securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale marketable securities, Cost	28,308	1,881
Available-for-sale marketable securities, Gross Unrealized Gain	2	'
Available-for-sale marketable securities, Gross Unrealized Loss	-20	'
Available-for-sale marketable securities, Estimated Fair Value	28,290	1,881
Short-term investments [Member] | Government agency securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale marketable securities, Cost	15,820	1,506
Available-for-sale marketable securities, Gross Unrealized Gain	4	2
Available-for-sale marketable securities, Gross Unrealized Loss	-22	'
Available-for-sale marketable securities, Estimated Fair Value	15,802	1,508
Short-term investments [Member] | Other securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale marketable securities, Cost	12,955	'
Available-for-sale marketable securities, Gross Unrealized Gain	3	'
Available-for-sale marketable securities, Gross Unrealized Loss	'	'
Available-for-sale marketable securities, Estimated Fair Value	12,958	'
Short-term investments [Member] | Amounts classified as cash equivalents [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale marketable securities, Cost	-64,583	-1,300
Available-for-sale marketable securities, Gross Unrealized Gain	-8	'
Available-for-sale marketable securities, Gross Unrealized Loss	'	'
Available-for-sale marketable securities, Estimated Fair Value	-64,591	-1,300
Investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale marketable securities, Cost	123,610	9,810
Available-for-sale marketable securities, Gross Unrealized Gain	19	11
Available-for-sale marketable securities, Gross Unrealized Loss	-77	-1
Available-for-sale marketable securities, Estimated Fair Value	123,552	9,820
Investments [Member] | United States government securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale marketable securities, Cost	20,636	2,145
Available-for-sale marketable securities, Gross Unrealized Gain	12	4
Available-for-sale marketable securities, Gross Unrealized Loss	'	'
Available-for-sale marketable securities, Estimated Fair Value	20,648	2,149
Investments [Member] | Corporate debt securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale marketable securities, Cost	42,578	1,970
Available-for-sale marketable securities, Gross Unrealized Gain	5	5
Available-for-sale marketable securities, Gross Unrealized Loss	-41	'
Available-for-sale marketable securities, Estimated Fair Value	42,542	1,975
Investments [Member] | Government agency securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale marketable securities, Cost	26,114	3,405
Available-for-sale marketable securities, Gross Unrealized Gain	'	1
Available-for-sale marketable securities, Gross Unrealized Loss	-23	-1
Available-for-sale marketable securities, Estimated Fair Value	26,091	3,405
Investments [Member] | Other securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale marketable securities, Cost	34,282	2,290
Available-for-sale marketable securities, Gross Unrealized Gain	2	1
Available-for-sale marketable securities, Gross Unrealized Loss	-13	'
Available-for-sale marketable securities, Estimated Fair Value	$34,271	$2,291

Investments_Additional_Informa

Investments - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Investments Debt And Equity Securities [Abstract]	'	'
Proceeds from sales of marketable securities	$23.40	$0

Investments_Schedule_of_Gross_

Investments - Schedule of Gross Realized Gains and Losses of Marketable Securities (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Investments Debt And Equity Securities [Abstract]	'	'
Gross realized gains	$2	'
Gross realized losses	'	'
Realized gains, net	$2	'

Investments_Schedule_of_Market

Investments - Schedule of Marketable Securities with Unrealized Losses (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'	'
Less Than 12 months, Fair Value	$122,369	$3,084
Less Than 12 months, Unrealized Loss	-119	-1
More than 12 months, Fair Value	'	'
More than 12 months, Unrealized Loss	'	'
Total, Fair Value	122,369	3,084
Total, Unrealized Loss	-119	-1
Corporate debt securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Less Than 12 months, Fair Value	52,382	1,180
Less Than 12 months, Unrealized Loss	-61	'
More than 12 months, Fair Value	'	'
More than 12 months, Unrealized Loss	'	'
Total, Fair Value	52,382	1,180
Total, Unrealized Loss	-61	'
Government agency securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Less Than 12 months, Fair Value	38,084	1,104
Less Than 12 months, Unrealized Loss	-45	-1
More than 12 months, Fair Value	'	'
More than 12 months, Unrealized Loss	'	'
Total, Fair Value	38,084	1,104
Total, Unrealized Loss	-45	-1
Other securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Less Than 12 months, Fair Value	31,903	800
Less Than 12 months, Unrealized Loss	-13	'
More than 12 months, Fair Value	'	'
More than 12 months, Unrealized Loss	'	'
Total, Fair Value	31,903	800
Total, Unrealized Loss	($13)	'

Investments_Schedule_of_Amorti

Investments - Schedule of Amortized Cost and Estimated Fair Value of Available-for-Sale Debt Securities by Contractual Maturity (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Investments Debt And Equity Securities [Abstract]	'	'
Mature in one year or less, Amortized Cost	$168,366	$10,134
Mature after one year through three years, Amortized Cost	143,153	9,810
Mature in more than three years, Amortized Cost	7,725	'
Total, Amortized Cost	319,244	19,944
Mature in one year or less, Estimated Fair Value	168,374	10,137
Mature after one year through three years, Estimated Fair Value	143,085	9,820
Mature in more than three years, Estimated Fair Value	7,719	'
Total, Estimated Fair Value	$319,178	$19,957

Derivative_Financial_Instrumen2

Derivative Financial Instruments - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Dec. 31, 2013
			Cash flow hedges [Member]	Cash flow hedges [Member]	Cash flow hedges [Member]	Cash flow hedges [Member]
			Fair Value of Derivatives Designated as Hedge Instruments [Member]	Fair Value of Derivatives Designated as Hedge Instruments [Member]	Fair Value of Derivatives Not Designated as Hedge Instruments [Member]	Fair Value of Derivatives Not Designated as Hedge Instruments [Member]
Derivatives, Fair Value [Line Items]	'	'	'	'	'	'
Net deferred loss associated with cash flow hedges	$0.20	'	'	'	'	'
Gain (loss) recognized for foreign currency forward contracts	-0.3	0.9	'	'	'	'
Notional principle amounts of Company's derivative instruments	'	'	$105.60	$96.60	$29.60	$24.20

Derivative_Financial_Instrumen3

Derivative Financial Instruments - Derivative Instruments at Gross Fair Value Reflected in Condensed Consolidated Balance Sheets (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Derivatives, Fair Value [Line Items]	'	'
Foreign exchange contracts, Assets	$1,140	$873
Foreign exchange contracts, Liabilities	-1,260	-1,555
Fair Value of Derivatives Designated as Hedge Instruments [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Foreign exchange contracts, Assets	867	782
Foreign exchange contracts, Liabilities	-1,065	-1,446
Fair Value of Derivatives Not Designated as Hedge Instruments [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Foreign exchange contracts, Assets	273	91
Foreign exchange contracts, Liabilities	($195)	($109)

Derivative_Financial_Instrumen4

Derivative Financial Instruments - Pre-tax Effect of Derivative Instruments Designated as Cash Flow Hedges in Condensed Consolidated Statements of Operations (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Gain Recognized in OCI - Effective Portion	$180	$735
Gain (Loss) Reclassified from AOCI into Income-Effective Portion	-274	34
Gain (Loss) Recognized - Ineffective Portion and Amount Excluded from Effectiveness Testing	'	-6
Foreign exchange contracts [Member] | Cash flow hedges [Member]	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Gain Recognized in OCI - Effective Portion	180	735
Gain (Loss) Reclassified from AOCI into Income-Effective Portion	-274	34
Foreign exchange contracts [Member] | Cash flow hedges [Member] | Foreign currency exchange gain (loss) and other [Member]	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Gain (Loss) Recognized - Ineffective Portion and Amount Excluded from Effectiveness Testing	'	($6)

Derivative_Financial_Instrumen5

Derivative Financial Instruments - Pre-tax Effect of Derivative Instruments Designated as Cash Flow Hedges in Condensed Consolidated Statements of Operations (Parenthetical) (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Net sales	$106,907	$91,938
Cost of sales	53,083	42,892
Reclassified from AOCI [Member] | Foreign exchange contracts [Member] | Cash flow hedges [Member]	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Net sales	500	700
Cost of sales	$200	$700

Intangible_Assets_and_Goodwill2

Intangible Assets and Goodwill - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization expense of intangible assets	$919	$1,560
Minimum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated useful lives of intangible assets	'3 years	'
Maximum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated useful lives of intangible assets	'15 years	'

Intangible_Assets_and_Goodwill3

Intangible Assets and Goodwill - Net Carrying Value and Accumulated Amortization of Major Classes of Intangible Assets (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	$52,938	$52,938
Accumulated Amortization	-38,612	-37,693
Net Carrying Amount	14,326	15,245
Licenses [Member]	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	28,577	28,577
Accumulated Amortization	-22,059	-21,597
Net Carrying Amount	6,518	6,980
Technology acquired in acquisitions [Member]	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	8,613	8,613
Accumulated Amortization	-8,613	-8,613
Customer relationships and other intangible assets acquired in acquisitions [Member]	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	15,748	15,748
Accumulated Amortization	-7,940	-7,483
Net Carrying Amount	$7,808	$8,265

Intangible_Assets_and_Goodwill4

Intangible Assets and Goodwill - Expected Future Annual Amortization Expense of Intangible Assets (Detail) (USD $)	Mar. 31, 2014
In Thousands, unless otherwise specified
Goodwill And Intangible Assets Disclosure [Abstract]	'
2014 (remaining nine months)	$2,760
2015	3,030
2016	2,429
2017	2,053
2018	1,972
Thereafter	2,082
Total expected future annual amortization	$14,326

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Income Tax Disclosure [Abstract]	'	'
Provision for income taxes	$680,000	$381,000
Percentage of effective tax rate differing from the statutory federal income tax rate	34.00%	34.00%
Difference in income tax benefit recorded in US federal and state tax jurisdictions for foreign jurisdictions	0	0
Income tax benefit recorded in US federal and state tax jurisdictions	$0	'
Income tax examination, description	'The Companybs 2000 through 2013 tax years generally remain open to examination by U.S. federal and most state tax authorities. In addition, the Company files tax returns in multiple foreign taxing jurisdictions with open tax years ranging from 2008 to 2013.	'

Convertible_Senior_Notes_Addit

Convertible Senior Notes - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended
	Feb. 28, 2014	Mar. 31, 2014
	Rate
Debt Instrument [Line Items]	'	'
Convertible notes issued	'	271,207,000
Convertible debt, present value of future payments	'	345,000,000
Initial strike price of common stock	'	65.1
Conversion of notes, cap price	'	78.61
Cost of purchased capped calls	'	25,100,000
Closing price of common stock	'	51.58
Equity component [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt instrument issuance costs	'	2,000,000
1.25% convertible senior notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Convertible notes issued	345,000,000	'
Convertible notes, maturity date	1-Feb-21	'
Convertible notes fixed rate	1.25%	'
Convertible senior notes, Maturity date description	'	'1.25% convertible senior notes (the "Notes") due February 1, 2021, unless earlier repurchased by the Company or converted by the holder pursuant to their terms
Convertible senior notes, interest payment description	'	'Interest is payable semiannually in arrears on February 1 and August 1 of each year, commencing on August 1, 2014.
Convertible debt, conversion rate	15.3616	'
Convertible debt, conversion rate, principal amount	1,000	'
Conversion price per share of common stock	$65.10	'
Debt converted into number of common shares	5,300,000	'
Convertible debt maturity date	1-Aug-20	'
1.25% convertible senior notes [Member] | Scenario two [Member]	'	'
Debt Instrument [Line Items]	'	'
Consecutive trading days	'5 days	'
Percentage of conversion price	98.00%	'
1.25% convertible senior notes [Member] | Scenario one [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt instrument trading days	20	'
Consecutive trading days	'30 days	'
Percentage of conversion price	130.00%	'
Senior, unsecured corporate bonds [Member]	'	'
Debt Instrument [Line Items]	'	'
Convertible debt, fair value of liability	'	270,000,000
Convertible debt, present value of future payments	'	345,000,000
Convertible debt discount, recorded in additional paid in capital	'	75,000,000
Convertible debt, interest rate	'	5.00%
Convertible senior notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt instrument issuance costs	'	7,200,000

Convertible_Senior_Notes_Sched

Convertible Senior Notes - Schedule of Convertible Notes (Detail) (USD $)	Mar. 31, 2014
In Thousands, unless otherwise specified
Liability component:	'
Principal	$345,000
Less: debt discount, net of amortization	-73,793
Net carrying amount	271,207
Equity component	$73,013

Convertible_Senior_Notes_Sched1

Convertible Senior Notes - Schedule of Convertible Notes (Parenthetical) (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Equity issuance costs	$2

Convertible_Senior_Notes_Sched2

Convertible Senior Notes - Schedule of Total Interest Expense Related to Notes (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Equity Method Investments And Cost Method Investments [Abstract]	'
1.25% coupon	$575
Amortization of debt issuance costs	50
Amortization of debt discount	1,207
Total interest expense	$1,832

Convertible_Senior_Notes_Sched3

Convertible Senior Notes - Schedule of Total Interest Expense Related to Notes (Parenthetical) (Detail)	Mar. 31, 2014
Equity Method Investments And Cost Method Investments [Abstract]	'
Coupon interest rate	1.25%

Convertible_Senior_Notes_Sched4

Convertible Senior Notes - Schedule of Carrying Value of Debt Instrument (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
Fair Value	$371,738	'
Carrying Value	271,207	'
Level 2 [Member]	'	'
Debt Instrument [Line Items]	'	'
Fair Value	371,738	'
Carrying Value	$271,207	'

Commitments_Contingencies_and_2

Commitments, Contingencies and Legal Matters - Summary of Purchase Commitments (Detail) (USD $)	Mar. 31, 2014
In Thousands, unless otherwise specified
Commitments And Contingencies Disclosure [Abstract]	'
2014 (remaining nine months)	$27,626
2015	1,944
2016	1,716
2017	1,716
2018	'
Thereafter	'
Total minimum payments	$33,002

Employee_Equity_Incentive_Plan2

Employee Equity Incentive Plans and Stock-Based Compensation Expense - Summary of Stock-Based Compensation Expense (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Total stock-based compensation expense	$6,782	$6,277
Cost of sales [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense	381	541
Research and development [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense	2,128	1,805
Sales and marketing [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense	1,616	1,299
General and administrative [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense	$2,657	$2,632

Employee_Equity_Incentive_Plan3

Employee Equity Incentive Plans and Stock-Based Compensation Expense - Summary of Option Activity (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Shares, Outstanding, Beginning Balance	6,476
Shares, Granted	149
Shares, Exercised	-1,000
Shares, Forfeited	-45
Shares, Outstanding, Ending Balance	5,580
Shares, Exercisable, March 31, 2014	3,173
Shares, Vested and expected to vest, March 31, 2014	5,370
Weighted Average Exercise Price, Outstanding, Beginning Balance	$26.70
Weighted Average Exercise Price, Granted	$49.65
Weighted Average Exercise Price, Exercised	$19.68
Weighted Average Exercise Price, Forfeited	$34.57
Weighted Average Exercise Price, Outstanding, Ending Balance	$28.50
Weighted Average Exercise Price, Exercisable, March 31, 2014	$21.46
Weighted Average Exercise Price, Vested and expected to vest, March 31, 2014	$28.09
Weighted Average Remaining Contractual Term, Outstanding, March 31, 2014	'3 years 11 months 16 days
Weighted Average Remaining Contractual Term, Exercisable, March 31, 2014	'2 years 8 months 12 days
Weighted Average Remaining Contractual Term, Vested and expected to vest, March 31, 2014	'3 years 10 months 21 days
Aggregate Intrinsic Value, Outstanding, March 31, 2014	$128,916
Aggregate Intrinsic Value, Exercisable, March 31, 2014	95,572
Aggregate Intrinsic Value, Vested and expected to vest, March 31, 2014	$126,279

Employee_Equity_Incentive_Plan4

Employee Equity Incentive Plans and Stock-Based Compensation Expense - Summary of Restricted Stock Plan Activity (Detail) (Restricted stock awards and restricted stock units [Member], USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014
Restricted stock awards and restricted stock units [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding, Beginning Balance, Shares	742
Granted, Shares	17
Vested/Released, Shares	-58
Cancelled, Shares	-20
Outstanding, Ending Balance, Shares	681
Weighted Average Grant Date Fair Value, Outstanding, Beginning Balance	$34.13
Weighted Average Grant Date Fair Value, Granted	$50.65
Weighted Average Grant Date Fair Value, Vested/Released	$31.88
Weighted Average Grant Date Fair Value, Cancelled	$37.26
Weighted Average Grant Date Fair Value, Outstanding, Ending Balance	$34.64

Employee_Equity_Incentive_Plan5

Employee Equity Incentive Plans and Stock-Based Compensation Expense - Summary of Assumptions to Estimate Fair Value (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Option Shares [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected Term (in years)	'4 years 5 months 1 day	'4 years 4 months 13 days
Volatility	0.43%	0.53%
Expected Dividends	'	'
Risk Free Interest Rates	1.66%	0.79%
Estimated Forfeitures	7.61%	7.63%
Weighted Average Fair Value Per Share	$18.43	$15.57
Employee Stock Purchase Plan [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected Term (in years)	'1 year 3 months	'1 year 3 months
Volatility	0.32%	0.46%
Expected Dividends	'	'
Risk Free Interest Rates	0.17%	0.19%
Weighted Average Fair Value Per Share	$14.54	$12.88

Segment_and_Significant_Concen2

Segment and Significant Concentrations - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
	Segment
Segment Reporting Information [Line Items]	'	'	'
Number of operating business segment	1	'	'
Percentage of direct customer to total product sales	10.00%	10.00%	'
Maximum percentage of accounts receivable by any one customer	22.00%	'	14.00%
Product sales to customers	$106,907,000	$91,938,000	'
Maximum sales contribution by any other country, percentage	10.00%	'	'
Maximum assets contribution by any other country, percentage	10.00%	'	'
U.S. [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Product sales to customers	61,600,000	59,600,000	'
Long lived-assets	76,300,000	'	63,900,000
Sweden and Countries in the European Monetary Union [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Long lived-assets	$20,600,000	'	21,000,000

Segment_and_Significant_Concen3

Segment and Significant Concentrations - Summary of Total Sales (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'
Total sales	$106,907	$91,938
Systems and other sales [Member]	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'
Total sales	18,529	16,010
Reagent and disposable sales [Member]	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'
Total sales	$88,378	$75,928

Segment_and_Significant_Concen4

Segment and Significant Concentrations - Sales Information by Segments (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Revenue from External Customer [Line Items]	'	'
Total sales	$106,907	$91,938
Clinical Systems [Member]	'	'
Revenue from External Customer [Line Items]	'	'
Total sales	17,285	12,537
Clinical Reagents [Member]	'	'
Revenue from External Customer [Line Items]	'	'
Total sales	83,160	67,049
Clinical [Member]	'	'
Revenue from External Customer [Line Items]	'	'
Total sales	100,445	79,586
Non-Clinical [Member]	'	'
Revenue from External Customer [Line Items]	'	'
Total sales	$6,462	$12,352

Segment_and_Significant_Concen5

Segment and Significant Concentrations - Segment Sales by Geography Region (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total sales	$106,907	$91,938
Clinical [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total sales	100,445	79,586
Non-Clinical [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total sales	6,462	12,352
North America [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total sales	62,835	63,556
North America [Member] | Clinical [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total sales	57,286	52,165
North America [Member] | Non-Clinical [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total sales	5,549	11,391
International [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total sales	44,072	28,382
International [Member] | Clinical [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total sales	43,159	27,421
International [Member] | Non-Clinical [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total sales	$913	$961

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail)	Mar. 31, 2014	Dec. 31, 2013	Apr. 22, 2014
			Subsequent Event [Member]
Subsequent Event [Line Items]	'	'	'
Common stock, shares authorized	100,000,000	100,000,000	150,000,000